Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/13/2017 01/17/2017 01/18/2017 01/19/2017 01/20/2017 Date
12.5(c) 11.8(c) 11.775(c) 11.45(c) 11.4(c) Last
978 160 1 823 382 754 612 749 292 870 437 Volume
-0.99% -5.60% -0.21% -2.76% -0.44% Change
More quotes
Financials ($)
Sales 2016 223 M
EBIT 2016 107 M
Net income 2016 17,7 M
Debt 2016 141 M
Yield 2016 -
Sales 2017 228 M
EBIT 2017 133 M
Net income 2017 66,8 M
Debt 2017 93,6 M
Yield 2017 -
P/E ratio 2016 23,27
P/E ratio 2017 6,37
EV / Sales2016 2,98x
EV / Sales2017 2,70x
Capitalization 523 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs in the Americas, Europe and Asia.It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic and... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
01/09 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Regulation FD Disclosu..
01/09 SUCAMPO PHARMACEUTICALS : Announces Pricing of $260.0 Million 3.25% Convertible ..
01/09 SUCAMPO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements a..
2016 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Entry into a Material ..
2016 SUCAMPO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Crea..
2016 SUCAMPO PHARMACEUTICALS : Announces Pricing of $260.0 Million 3.25% Convertible ..
2016 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Announces Its New Debt Offering Of ..
2016 Sucampo Announces Pricing of $260.0 Million 3.25% Convertible Senior Notes du..
2016 SUCAMPO PHARMACEUTICALS : Announces Proposed Convertible Senior Note Offering
2016 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Regulation FD Disclosu..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
2015The bullish trend is not over
More Strategies
Latest Tweets
01/18Biotech Forum Daily Digest: Sector Gets 'Trumped' Again - Spotlight On Sucamp.. 
01/17Such a great photo from @mykalmphoto of Andrew Smith's father, Curt, celebrat..
15
01/14Former Butler Basketball player Andrew Smith continues to touch lives in the ..
4
01/14#Top25 small, fast-growing cos w/ potential to become #market leaders $DIOD $..
1
01/13Legacy of former Butler basketball standout Andrew Smith continues to touch l..
1
More tweets
Qtime:80
News from SeekingAlpha
01/18 BIOTECH FORUM DAILY DIGEST : Sector Gets 'Trumped' Again - Spotlight On Sucampo ..
2016 Recent analyst action
2016 Midday Gainers / Losers
2016 After-hours Gainers / Losers
2016 Sucampo readies $225M private offering of convertible debt; shares slip 5% af..
Advertisement
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Technical analysis trends SUCAMPO PHARMACEU...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 19,0 $
Spread / Average Target 67%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Daniel P. Getman Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICAL..-15.87%523
AMGEN, INC.5.79%115 062
GILEAD SCIENCES, INC.-0.84%93 553
CELGENE CORPORATION-2.67%87 334
REGENERON PHARMACEUTIC..-1.23%38 239
ACTELION LTD1.18%23 977
More Results